- Home
- PMT vs GYRE Comparison
PMT vs GYRE Comparison
Compare PMT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMT
- GYRE
- Stock Information
- Founded
- PMT 2009
- GYRE 2002
- Country
- PMT United States
- GYRE United States
- Employees
- PMT N/A
- GYRE N/A
- Industry
- PMT Real Estate Investment Trusts
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- PMT Real Estate
- GYRE Health Care
- Exchange
- PMT Nasdaq
- GYRE Nasdaq
- Market Cap
- PMT 1.1B
- GYRE 897.1M
- IPO Year
- PMT 2009
- GYRE N/A
- Fundamental
- Price
- PMT $12.27
- GYRE $7.83
- Analyst Decision
- PMT Hold
- GYRE Strong Buy
- Analyst Count
- PMT 6
- GYRE 1
- Target Price
- PMT $14.20
- GYRE $18.00
- AVG Volume (30 Days)
- PMT 631.6K
- GYRE 98.4K
- Earning Date
- PMT 10-21-2025
- GYRE 11-12-2025
- Dividend Yield
- PMT 13.06%
- GYRE N/A
- EPS Growth
- PMT N/A
- GYRE N/A
- EPS
- PMT 0.72
- GYRE 0.02
- Revenue
- PMT $614,826,000.00
- GYRE $102,189,000.00
- Revenue This Year
- PMT N/A
- GYRE $18.39
- Revenue Next Year
- PMT $28.12
- GYRE $48.26
- P/E Ratio
- PMT $17.03
- GYRE $170.75
- Revenue Growth
- PMT 13.07
- GYRE N/A
- 52 Week Low
- PMT $11.70
- GYRE $6.11
- 52 Week High
- PMT $14.93
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- PMT 48.59
- GYRE 50.33
- Support Level
- PMT $12.36
- GYRE $7.55
- Resistance Level
- PMT $12.47
- GYRE $8.56
- Average True Range (ATR)
- PMT 0.20
- GYRE 0.53
- MACD
- PMT 0.01
- GYRE -0.00
- Stochastic Oscillator
- PMT 30.82
- GYRE 52.60
About PMT PennyMac Mortgage Investment Trust of Beneficial Interest
PennyMac Mortgage Investment Trust is a specialty finance company that invests primarily in residential mortgage loans and mortgage-related assets. The company's operations include activities such as the production and servicing of financial securities based on residential loans and the pooling and reselling of high-credit-quality mortgages. The company operates through three segments: correspondent production, credit-sensitive strategies, interest-rate-sensitive strategies. The Credit sensitive strategies segment generates income via investments in CRT arrangements, subordinate MBS, distressed loans, and real estate.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.